You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

CLINICAL TRIALS PROFILE FOR AFLIBERCEPT


✉ Email this page to a colleague

« Back to Dashboard


Biosimilar Clinical Trials for aflibercept

This table shows clinical trials for biosimilars. See the next table for all clinical trials
Trial ID Title Status Sponsor Phase Start Date Summary
NCT04450329 ↗ A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD) Active, not recruiting Samsung Bioepis Co., Ltd. Phase 3 2020-06-23 This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy, safety, PK, and immunogenicity of SB15 compared to Eylea® in subjects with neovascular AMD.
NCT04480463 ↗ A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) Recruiting Sam Chun Dang Pharm. Co. Ltd. Phase 3 2020-08-13 Age-related macular degeneration (AMD) is a leading cause of vision loss in adults. Abnormal blood vessels grow under the macula at the back of the eye, and also leak blood and fluid, which damages and scars the macula, affecting vision. The current standard of care for patients with neovascular (exudative / wet) AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy, which prevents or slows down the growth of the abnormal blood vessels. SCD411 is being developed as a biosimilar to the reference product Eylea® (aflibercept), an anti-VEGF drug. The study aims to prove equivalence of SCD411 to Eylea in adults with wet AMD, and will look at safety, tolerance, effectiveness, immune response and the movement of the drug through the body.
NCT04522167 ↗ Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration Recruiting Bioeq GmbH Phase 3 2020-07-21 This is a randomized, double-masked, multicenter study to evaluate the efficacy and safety of FYB203 compared to Eylea® in patients with neovascular age related macular degeneration.
NCT05161806 ↗ Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe Not yet recruiting Sandoz Phase 3 2022-01-25 This is a multicenter, open label Phase IIIb study to evaluate the safety of use of a Prefilled syringe (PFS) containing SOK583A1 (40 mg/mL) and to support the collection of observations of the PFS use for intravitreal injection, when utilized by qualified ophthalmologists, who follow the Instructions for Use (IFU) appropriately to prepare and administer Intravitreal (IVT) injections to patients, suffering from nAMD.
NCT05282004 ↗ Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit Not yet recruiting Sandoz Phase 3 2022-03-08 This is a single-arm, open-label study where all patients will receive a single injection of SOK583A1 (40 mg/mL) provided in a vial kit at Baseline. The total study duration for the individual participant is approximately 31 days.
NCT05345236 ↗ A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD) Completed Qilu Pharmaceutical Co., Ltd. Phase 3 2019-08-19 This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy and safety of QL1207 compared to Eylea® in subjects with wet AMD.
>Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for aflibercept

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00284141 ↗ Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma Completed Regeneron Pharmaceuticals Phase 2 2006-01-01 This study evaluated the efficacy and safety of aflibercept in the treatment of participants with advanced chemoresistant non-small cell lung adenocarcinoma (NSCLA). Primary objective: - To determine the overall objective response rate (ORR) of AVE0005 (ziv-aflibercept, aflibercept, VEGF trap, ZALTRAP®) 4.0 mg/kg intravenously (IV) every 2 weeks in participants with platinum- and erlotinib-resistant, locally advanced or metastatic NSCLA. Secondary objective: - To assess duration of response (DR), progression-free survival (PFS), and overall survival (OS) in this participant population - To evaluate the safety profile of IV AVE0005 (ziv-aflibercept, aflibercept, VEGF trap, ZALTRAP®). This study employed an Independent Review Committee (IRC) for radiological tumor assessments. For all tumor assessment-related efficacy variables, two analyses were performed: the primary analysis was based on Independent Review Committee (IRC) reviewed data and the secondary analysis was based on Investigator evaluation. In addition, both Response Evaluation Criteria In Solid Tumors (RECIST) and Modified Response Evaluation Criteria In Solid Tumors (mRECIST) were used to assess tumors. Where as RECIST criteria only consider the longest diameter of the tumors for calculations pertaining to changes in tumor size, mRECIST assessments also account for the differences in the cavities of lesions observed in non-small-cell lung cancer (NSCLC). Responses based on RECIST and mRECIST are reported.
NCT00284141 ↗ Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma Completed Sanofi Phase 2 2006-01-01 This study evaluated the efficacy and safety of aflibercept in the treatment of participants with advanced chemoresistant non-small cell lung adenocarcinoma (NSCLA). Primary objective: - To determine the overall objective response rate (ORR) of AVE0005 (ziv-aflibercept, aflibercept, VEGF trap, ZALTRAP®) 4.0 mg/kg intravenously (IV) every 2 weeks in participants with platinum- and erlotinib-resistant, locally advanced or metastatic NSCLA. Secondary objective: - To assess duration of response (DR), progression-free survival (PFS), and overall survival (OS) in this participant population - To evaluate the safety profile of IV AVE0005 (ziv-aflibercept, aflibercept, VEGF trap, ZALTRAP®). This study employed an Independent Review Committee (IRC) for radiological tumor assessments. For all tumor assessment-related efficacy variables, two analyses were performed: the primary analysis was based on Independent Review Committee (IRC) reviewed data and the secondary analysis was based on Investigator evaluation. In addition, both Response Evaluation Criteria In Solid Tumors (RECIST) and Modified Response Evaluation Criteria In Solid Tumors (mRECIST) were used to assess tumors. Where as RECIST criteria only consider the longest diameter of the tumors for calculations pertaining to changes in tumor size, mRECIST assessments also account for the differences in the cavities of lesions observed in non-small-cell lung cancer (NSCLC). Responses based on RECIST and mRECIST are reported.
NCT00320775 ↗ Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD Completed Bayer Phase 1 2005-06-01 The purpose of this trial is to assess the ocular and systemic safety and tolerability of a single intravitreal injection of VEGF Trap in patients with subfoveal choroidal neovascularization (CNV) due to AMD.
NCT00320775 ↗ Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD Completed Regeneron Pharmaceuticals Phase 1 2005-06-01 The purpose of this trial is to assess the ocular and systemic safety and tolerability of a single intravitreal injection of VEGF Trap in patients with subfoveal choroidal neovascularization (CNV) due to AMD.
NCT00327171 ↗ Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer Completed Regeneron Pharmaceuticals Phase 2 2006-05-01 This study evaluated outcomes in participants with advanced ovarian epithelial adenocarcinoma receiving aflibercept. The primary objective was to compare the objective response rate of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) 4.0 mg/kg and 2.0 mg/kg, administered intravenously (IV) every 2 weeks with historical control in participants with advanced ovarian epithelial (including fallopian tube and primary peritoneal) adenocarcinoma resistant to platinum and topotecan and/or liposomal doxorubicin. The secondary objectives was to further assess efficacy, safety, pharmacokinetics, potential biological and pharmacogenomic markers of study drug activity, and health-related quality of life. This study employed an Independent Review Committee (IRC) for radiological tumor assessments. For all tumor assessment-related efficacy variables, two analyses were performed: the primary analysis was based on Independent Review Committee (IRC) reviewed data and the secondary analysis was based on Investigator evaluation. If an endpoint was evaluated by the IRC, the IRC reviewed data is reported for this study.
NCT00327171 ↗ Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer Completed Sanofi Phase 2 2006-05-01 This study evaluated outcomes in participants with advanced ovarian epithelial adenocarcinoma receiving aflibercept. The primary objective was to compare the objective response rate of Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) 4.0 mg/kg and 2.0 mg/kg, administered intravenously (IV) every 2 weeks with historical control in participants with advanced ovarian epithelial (including fallopian tube and primary peritoneal) adenocarcinoma resistant to platinum and topotecan and/or liposomal doxorubicin. The secondary objectives was to further assess efficacy, safety, pharmacokinetics, potential biological and pharmacogenomic markers of study drug activity, and health-related quality of life. This study employed an Independent Review Committee (IRC) for radiological tumor assessments. For all tumor assessment-related efficacy variables, two analyses were performed: the primary analysis was based on Independent Review Committee (IRC) reviewed data and the secondary analysis was based on Investigator evaluation. If an endpoint was evaluated by the IRC, the IRC reviewed data is reported for this study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for aflibercept

Condition Name

Condition Name for aflibercept
Intervention Trials
Diabetic Macular Edema 61
Neovascular Age-related Macular Degeneration 36
Macular Edema 18
Diabetic Retinopathy 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for aflibercept
Intervention Trials
Macular Degeneration 123
Macular Edema 106
Edema 76
Wet Macular Degeneration 72
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for aflibercept

Trials by Country

Trials by Country for aflibercept
Location Trials
Japan 191
Italy 117
Germany 95
Spain 91
Canada 89
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for aflibercept
Location Trials
California 78
Texas 77
Florida 55
New York 53
Maryland 49
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for aflibercept

Clinical Trial Phase

Clinical Trial Phase for aflibercept
Clinical Trial Phase Trials
Phase 4 93
Phase 3 72
Phase 2/Phase 3 10
[disabled in preview] 132
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for aflibercept
Clinical Trial Phase Trials
Completed 178
Recruiting 55
Unknown status 34
[disabled in preview] 71
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for aflibercept

Sponsor Name

Sponsor Name for aflibercept
Sponsor Trials
Regeneron Pharmaceuticals 98
Bayer 48
Sanofi 39
[disabled in preview] 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for aflibercept
Sponsor Trials
Industry 289
Other 275
NIH 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.